SOPHiA GENETICS Unveils New Generation of the SOPHiA DDMTM Platform at Morgan Stanley Healthcare Conference 2024

Rhea-AI Summary

SOPHiA GENETICS (Nasdaq: SOPH) has unveiled the new generation of its SOPHiA DDM™ Platform at the Morgan Stanley Healthcare Conference 2024. This cloud-native platform offers a new web-based architecture designed to compute large amounts of data more efficiently at-scale, while enhancing customer experience with integrated access to multimodal analytics modules.

The platform now processes nearly 30,000 analyses per month, with over 1.8 million genomic profiles analyzed to date. The new generation introduces faster data processing, enabling quicker turnaround times and new capabilities such as whole genome sequencing. It integrates genomic, radiomic, and multimodal analytics in a single workspace, allowing customers to select applications that best suit their needs.

Positive

• New platform architecture enables more efficient data processing and faster turnaround times
• Integration of genomic, radiomic, and multimodal analytics in a single workspace
• Platform processes nearly 30,000 analyses per month
• Over 1.8 million genomic profiles analyzed to date
• New whole genome sequencing application to be released later this year

Negative

• None.

New generation of SOPHiA DDM^TM integrates latest advancements in data processing and technology to deliver elevated experience and capabilities to customers

BOSTON and ROLLE, Switzerland, Sept. 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today launched the new generation of the SOPHiA DDM^TM Platform. The new-gen SOPHiA DDM^TM Platform offers a new architecture designed to more efficiently compute large amounts of data at-scale, while elevating customer experience with integrated access to multimodal analytics modules.

As cancer cases continue to rise across the globe, our understanding of the disease becomes more nuanced. Newer, more effective therapies are being developed each day, and data is becoming increasingly critical in diagnosis, therapy selection, and drug development. Since launching the first generation of SOPHiA DDM ^TM in 2015, the Platform has been at the forefront of these innovations, accelerating the practice of data driven medicine globally as a leading platform in healthcare for using data to improve patient care. Data computed daily by the Platform has surged over the years with over 1.8 million genomic profiles being analyzed on the platform, at a rate of almost 30,000 analyses per month.

As the volume and utility of data grows, SOPHiA GENETICS continues to accelerate innovation in the field of data-driven medicine by unveiling best-in-class technology and data science capabilities. The new generation SOPHiA DDM ^TM Platform offers a new, web-based architecture, which allows the Platform to compute and process data more efficiently by leveraging microservices as well as the newest technologies in cloud computing and GPUs from partners such as NVIDIA and Microsoft.

Faster data processing not only optimizes computing, but it also provides answers more rapidly. Customers will experience faster turnaround time from data upload to insights. In addition, more efficient data processing capabilities enable the launch of new capabilities, such as the new whole genome sequencing (WGS) application being released later this year. It also enables new capabilities in multimodal analytics, which require processing of more complex and sizeable data sets across data modalities.

Under the new generation of SOPHiA DDM^TM, genomic, radiomic, and multimodal analytics capabilities will be offered in a single, integrated workspace. Customers benefit from the three analytics modules by selecting applications that best suit their needs:

• Genomics: Ingests genomics FASTQ and VCF data to efficiently call, annotate, and pre-classify oncogenic or pathogenic variants.
• Radiomics: Processes data from various imaging modalities (e.g., CT scans, PET-CT, MRI), segments anatomical areas of interest, and extracts radiomic features for further analysis.
• Multimodal: Aggregates data from the radiomics and genomics modules, along with processed clinical, biological, and histological data, to train and verify predictive models at the individual patient level.

"As our understanding of diseases becomes even more nuanced, we need to continue to grow and adapt our solutions to be able to field this complexity with speed and accuracy. Our customers are relying on us to provide them with innovative solutions that can accelerate their workflows," said Zhenyu Xu, Chief Scientific Officer, SOPHiA GENETICS. "Our decentralized, multimodal analytics platform supports customers and helps break data silos by creating a global community where knowledge is safely and securely shared amongst users. The new generation of our SOPHiA DDM^TM Platform is revolutionizing the user experience by blending our powerful AI algorithms with multimodal data to produce meaningful insights to further the field of precision medicine."

Abhimanyu Verma, Chief Technology Officer, SOPHiA GENETICS, added, "We pride ourselves on adapting our technology to meet our customers' needs. As the technology infrastructure at most healthcare organizations worldwide has evolved, we are thrilled to continue to provide best-in-class technology and set them up for success. This new generation of our platform will allow us the flexibility to respond quickly to our customer's evolving needs and introduce new features faster, and more efficiently."

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM and connect on LinkedIn. 

About SOPHiA GENETICS 
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to unlock insights to deliver world-class care to patients across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.  For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. 

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-unveils-new-generation-of-the-sophia-ddmtm-platform-at-morgan-stanley-healthcare-conference-2024-302237655.html

SOURCE SOPHiA GENETICS

FAQ

What new features does the SOPHiA DDM™ Platform offer in its latest generation?

The new generation SOPHiA DDM™ Platform offers a web-based architecture for more efficient data processing, faster turnaround times, and integrated access to genomic, radiomic, and multimodal analytics modules in a single workspace.

How many genomic profiles has SOPHiA GENETICS (SOPH) analyzed on its platform?

SOPHiA GENETICS has analyzed over 1.8 million genomic profiles on its SOPHiA DDM™ Platform, processing nearly 30,000 analyses per month.

When will SOPHiA GENETICS (SOPH) release its new whole genome sequencing application?

SOPHiA GENETICS plans to release its new whole genome sequencing (WGS) application later in 2024, as part of the new generation SOPHiA DDM™ Platform capabilities.

What are the three analytics modules offered in the new SOPHiA DDM™ Platform?

The new SOPHiA DDM™ Platform offers three integrated analytics modules: Genomics for variant analysis, Radiomics for imaging data processing, and Multimodal for aggregating data from various sources to train and verify predictive models.